Baird Medical Investment Holdings Limited (BDMD) is a Cayman Islands-incorporated medical device company whose operations are based in Guangzhou, China. It develops microwave ablation (MWA) systems and disposable ablation needles used in minimally invasive treatment of thyroid nodules, liver, lung and breast tumors, and is launching an FDA-cleared MWA system in the United States while building out irreversible electroporation (IRE) products and an AI-powered robotic ablation platform.
The stock fell 13.24% to $0.0924 in Tuesday's session, compared with a prior close of $0.1065 on Monday, November 16. The direction is clearly negative. The catalyst is verifiable and was published after Monday's closing bell: proxy materials for a November 30 shareholder meeting proposing a reverse split, a super-voting share class, and a large related-party share cancellation.
Monday's filing sets up five proposals for the November 30 extraordinary general meeting, to be held in Guangzhou. The centerpiece is a 1-for-50 consolidation of Class A, Class B and Series A preferred shares, which would shrink the issued share count from roughly 56.5 million ordinary shares to about 1.1 million and, on paper, lift the quoted price by a factor of 50 — implying a level near $4.60 based on Tuesday's trading rather than roughly nine cents.
The filing also restructures the authorized capital into 480 million Class A shares, 20 million Class B shares carrying 100 votes each, and 5 million Series A convertible preferred shares. Existing ordinary shares would be redesignated one-for-one as Class A shares. Separately, the company proposes repurchasing and cancelling 18,195,281 Class A shares for total consideration of $1,819.53, funded by issuing the same number of Class B shares to the holder.
Markets read that combination defensively. A consolidation changes no underlying value, and reverse splits in sub-$1 micro-caps have a long record of being followed by renewed weakness. Layering a 100-vote Class B class on top, plus a share cancellation funded with new super-voting stock, concentrates control with the founder and raises dilution and governance questions for minority holders — a plausible and sufficient explanation for a double-digit decline on a stock with a market value of only about $3.4 million.
On November 2, the company was notified that its closing bid had stayed below $1.00 for 30 consecutive business days, breaching Nasdaq Listing Rule 5550(a)(2). It has until May 3, 2027 to regain compliance, which requires a closing bid of at least $1.00 for ten consecutive sessions, with a possible additional 180-day grace period. Trading continues uninterrupted, but the deficiency keeps listing risk front and center. The reverse split is the board's proposed remedy; investors are pricing the odds that it works, and the cost of achieving it.
The decline is also consistent with speculative trading in a thinly held low-priced name. The float is small relative to the share count, spreads are wide, and the stock has swung by double digits with regularity: it has logged roughly 14 sessions since mid-September with absolute moves of 13% or more, including a 47.9% jump and a 44.1% drop in early November. Turnover has also exploded, running in the millions of shares a session since late October versus tens of thousands in September. In that environment, modest order flow moves the quote far more than news alone would.
Volume has been elevated for weeks, averaging roughly 15 million shares a day recently, a dramatic step-up from the quiet autumn sessions. The move was company-specific rather than sector-driven: no peer in thermal ablation or surgical devices disclosed comparable news, and the decline diverged from a generally firmer broader tape. Technically, shares have surrendered the $0.10 handle and remain far below their 50- and 200-day moving averages, a structure consistent with persistent downside momentum. The key reference is the $0.0725 52-week low; a break there would put the stock at its weakest level in a year.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative news and an extreme, rare price move. Baird Medical earns 36 out of 100. The verified news is genuinely material for a company of this size: a reverse split, a dual-class conversion and a related-party share cancellation, all aimed at surviving a Nasdaq listing deficiency. But it is structural rather than operational — no revenue, trial or regulatory surprise — so it does not rank as transformative. Today's 13.24% decline was about 1.7 times the stock's typical daily move, and moves of that magnitude or larger have occurred 14 times in the past 60 sessions, so the anomaly component is small. Moderate news plus an unremarkable anomaly for this name combine into a middling score.
All eyes are on the November 30 meeting, which is scheduled for 10:00 a.m. Guangzhou time on December 1 locally — the evening of November 29 in New York — and on whether the consolidation takes effect with Nasdaq confirmation. Shareholder approval of the Class B structure and the cancellation mechanics will determine the post-vote share count and voting control. The company's next financial report has not been scheduled; its last filing covered the six months ended June 30, when revenue rose 24.6% to $9.91 million and net income turned positive at $0.13 million. Investors will want to see whether that improvement persists and whether liquidity — thin cash reserves and reliance on convertible financing — is stabilized. Regulatory decisions on the IRE system in the U.S. and EU are targeted for 2027, and the China Resources distribution rollout will be watched for order conversion. Principal risks are delisting, continued dilution, and governance changes that reduce minority influence.
Tickeron's Trending AI Robots page is a curated window into the platform's automated trading strategies. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions are surfaced in this section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as conditions change. For traders seeking systematic exposure without hand-screening thousands of names, review the current leaders and compare their statistics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BDMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 25 of 31 cases where BDMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BDMD's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on BDMD as a result. In 32 of 72 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 44%.
The Moving Average Convergence Divergence (MACD) for BDMD just turned positive on November 11, 2026. Looking at past instances where BDMD's MACD turned positive, the stock continued to rise in 20 of 46 cases over the following month. The odds of a continued upward trend are 43%.
Following a +10.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDMD advanced for three days, in 70 of 120 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for BDMD entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.081) is normal, around the industry mean (4.142). P/E Ratio (-0.159) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.371) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 98 (best 1 - 100 worst), indicating slightly worse than average price growth. BDMD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices